{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T13:22:09Z","timestamp":1783171329529,"version":"3.54.6"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["Me 1009\/23 & Me 865\/15"],"award-info":[{"award-number":["Me 1009\/23 & Me 865\/15"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.bmc.2026.118678","type":"journal-article","created":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T14:44:41Z","timestamp":1777214681000},"page":"118678","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["5,6,7,8-Tetrahydroimidazo[1,2-a]pyrazine-based thiosemicarbazones as anti-Trypanosoma cruzi agents"],"prefix":"10.1016","volume":"139","author":[{"given":"Marlene Saraiva","family":"de Ara\u00fajo Neta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u00edsa Cavalcanti","family":"Coelho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe Neves","family":"Coutinho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9ria R\u00eago Alves","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo Zaldini","family":"Hernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafaela Salgado","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Policarpo Ademar Sales","family":"Junior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvane Maria Fonseca","family":"Murta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Ourliac-Garnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc-Antoine","family":"Bazin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Courtioux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clotilde","family":"Boudot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline Caroline","family":"da Silva Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiz Felipe Gomes Rebello","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luan Carvalho","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Thi\u00e9faine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Brenot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Jaime Bezerra","family":"Mendon\u00e7a-Junior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresinha Gon\u00e7alves","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ant\u00f4nio Rodolfo","family":"de Faria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Marchand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2026.118678_bb0005","unstructured":"World Health Organization. Chagas disease (also known as American trypanosomiasis). Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/chagas-disease-(american-trypanosomiasis) (accessed January 4, 2026)."},{"key":"10.1016\/j.bmc.2026.118678_bb0010","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2019.00166","article-title":"Chagas disease: from discovery to a worldwide health problem","volume":"7","author":"Lidani","year":"2019","journal-title":"Front Public Health"},{"key":"10.1016\/j.bmc.2026.118678_bb0015","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2017.00607","article-title":"The complement system: a prey of Trypanosoma cruzi","volume":"8","author":"Lidani","year":"2017","journal-title":"Front Microbiol"},{"key":"10.1016\/j.bmc.2026.118678_bb0020","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0140-6736(17)31612-4","article-title":"Chagas disease","volume":"391","author":"P\u00e9rez-Molina","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.bmc.2026.118678_bb0025","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1021\/acsinfecdis.2c00123","article-title":"An updated view of the Trypanosoma cruzi life cycle: intervention points for an effective treatment","volume":"8","author":"Mart\u00edn-Escolano","year":"2021","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.bmc.2026.118678_bb0030","article-title":"A systematic review of historical and current trends in Chagas disease","volume":"8","author":"\u00c1lvarez-Hern\u00e1ndez","year":"2021","journal-title":"Ther Adv Infect Dis"},{"key":"10.1016\/j.bmc.2026.118678_bb0035","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/bcp.14700","article-title":"Review of pharmacological options for the treatment of chagas disease","volume":"88","author":"Lascano","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.bmc.2026.118678_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.actatropica.2015.12.017","article-title":"Current drug therapy and pharmaceutical challenges for Chagas disease","volume":"156","author":"Bermudez","year":"2016","journal-title":"Acta Trop"},{"key":"10.1016\/j.bmc.2026.118678_bb0045","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2147\/JEP.S267378","article-title":"Review on experimental treatment strategies against Trypanosoma cruzi","volume":"13","author":"Mazzeti","year":"2021","journal-title":"J Exp Pharmacol"},{"key":"10.1016\/j.bmc.2026.118678_bb0050","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ijpddr.2019.11.004","article-title":"Current trends in the pharmacological management of chagas disease","volume":"12","author":"Ribeiro","year":"2020","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"10.1016\/j.bmc.2026.118678_bb0055","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.2174\/0929867323999160625124424","article-title":"Challenges in Chagas disease drug discovery. Reviews in Medicinal Chemistry: a review","volume":"23","author":"Paucar","year":"2016","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.bmc.2026.118678_bb0060","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.2174\/0929867322666151015120804","article-title":"Current and future chemotherapy for Chagas disease","volume":"22","author":"Gaspar","year":"2015","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.bmc.2026.118678_bb0065","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.ejmech.2018.06.040","article-title":"Current advances in drug discovery for chagas disease","volume":"155","author":"Scarim","year":"2018","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118678_bb0070","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/cbdd.14257","article-title":"A comprehensive review on potential candidates for the treatment of chagas disease","volume":"102","author":"Pathak","year":"2023","journal-title":"Chem Biol Drug Des"},{"key":"10.1016\/j.bmc.2026.118678_bb0075","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2021.771143","article-title":"Chagas disease drug discovery in Latin America\u2014a mini review of antiparasitic agents explored between 2010 and 2021","volume":"9","author":"de Oliveira","year":"2021","journal-title":"Front Chem"},{"key":"10.1016\/j.bmc.2026.118678_bb0080","article-title":"Chagas disease treatment and rational drug discovery: a challenge that remains","volume":"10","author":"Cristov\u00e3o-Silva","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.bmc.2026.118678_bb0085","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4155\/ppa-2022-0005","article-title":"Pharmaceutical agents for the treatment of chagas disease: patenting trends in the 2016-2021 period","volume":"11","author":"Flores-Quiroz","year":"2022","journal-title":"Pharm Patent Anal"},{"key":"10.1016\/j.bmc.2026.118678_bb0090","article-title":"Hit-to-lead optimization of a 2-aminobenzimidazole series as new candidates for Chagas disease","volume":"246","author":"de Oliveira Rezende","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118678_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112692","article-title":"The role of imidazole and benzimidazole heterocycles in chagas disease: a review","volume":"206","author":"Beltran-Hortelano","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118678_bb0100","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1021\/acs.jmedchem.2c00775","article-title":"Collaborative virtual screening identifies a 2-Aryl-4-aminoquinazoline series with efficacy in an in vivo model of trypanosoma cruzi infection","volume":"66","author":"Tawaraishi","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118678_bb0105","doi-asserted-by":"crossref","first-page":"10413","DOI":"10.1021\/acs.jmedchem.3c00582","article-title":"Structure-guided design and synthesis of a pyridazinone series of trypanosoma cruzi proteasome inhibitors","volume":"66","author":"Thomas","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118678_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114421","article-title":"Identification and development of a series of disubstituted piperazines for the treatment of chagas disease","volume":"238","author":"McGonagle","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118678_bb0115","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1021\/acs.jmedchem.9b01852","article-title":"Discovery and optimization of a compound series active against trypanosoma cruzi, the causative agent of chagas disease","volume":"63","author":"Harrison","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118678_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112849","article-title":"Re-evaluating pretomanid analogues for Chagas disease: hit-to-lead studies reveal both in vitro and in vivo trypanocidal efficacy","volume":"207","author":"Thompson","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118678_bb0125","doi-asserted-by":"crossref","first-page":"10362","DOI":"10.1021\/acs.jmedchem.9b01429","article-title":"Chagas disease drug discovery: multiparametric lead optimization against trypanosoma cruzi in acylaminobenzothiazole series","volume":"62","author":"Fleau","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118678_bb0130","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1021\/acs.jmedchem.2c01725","article-title":"Novel diarylthioether compounds as agents for the treatment of chagas disease","volume":"66","author":"Beveridge","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118678_bb0135","first-page":"1","article-title":"State-of-the-art in the drug discovery pathway for chagas disease: a framework for drug development and target validation","volume":"14","author":"Gabald\u00f3n-Figueira","year":"2023","journal-title":"Res RepTrop Med"},{"key":"10.1016\/j.bmc.2026.118678_bb0140","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1080\/13543784.2020.1793955","article-title":"Emerging agents for the treatment of Chagas disease: what is in the preclinical and clinical development pipeline?","volume":"29","author":"Mart\u00ednez-Peinado","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.bmc.2026.118678_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.actatropica.2019.105107","article-title":"Drug discovery for chagas disease: a viewpoint","volume":"198","author":"Kratz","year":"2019","journal-title":"Acta Trop"},{"key":"10.1016\/j.bmc.2026.118678_bb0150","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1080\/17460441.2019.1652593","article-title":"Advances in preclinical approaches to chagas disease drug discovery","volume":"14","author":"Villalta","year":"2019","journal-title":"Expert OpinDrug Discov"},{"key":"10.1016\/j.bmc.2026.118678_bb0155","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nature19339","article-title":"Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness","volume":"537","author":"Khare","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2026.118678_bb0160","doi-asserted-by":"crossref","first-page":"10773","DOI":"10.1021\/acs.jmedchem.0c00499","article-title":"Discovery and characterization of clinical candidate LXE408 as a Kinetoplastid-selective proteasome inhibitor for the treatment of leishmaniases","volume":"63","author":"Nagle","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118678_bb0165","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/s41564-022-01211-y","article-title":"Discovery of an orally active benzoxaborole prodrug effective in the treatment of chagas disease in non-human primates","volume":"7","author":"Padilla","year":"2022","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.bmc.2026.118678_bb0170","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.pt.2023.03.015","article-title":"Effective drug discovery in chagas disease","volume":"39","author":"Tarleton","year":"2023","journal-title":"Trends Parasitol"},{"key":"10.1016\/j.bmc.2026.118678_bb0175","first-page":"16159","article-title":"DNDI-6148: a novel benzoxaborole preclinical candidate for the treatment of visceral leishmaniasis","volume":"64","author":"Mowbray","year":"2021","journal-title":"JMed Chem"},{"key":"10.1016\/j.bmc.2026.118678_bb0180","unstructured":"Drugs for Neglected Diseases initiative (DNDI). DNDI-6148 Chagas disease. Available online: https:\/\/dndi.org\/research-development\/portfolio\/dndi-6148-chagas\/ (acessed December 4, 2025)."},{"key":"10.1016\/j.bmc.2026.118678_bb0185","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/17460441.2018.1417380","article-title":"Phenotypic screening approaches for chagas disease drug discovery","volume":"13","author":"Chatelain","year":"2018","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.bmc.2026.118678_bb0190","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1517\/17460441.2016.1160883","article-title":"Novel drug discovery for chagas disease","volume":"11","author":"Moraes","year":"2016","journal-title":"Expert OpinDrug Discov"},{"key":"10.1016\/j.bmc.2026.118678_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116577","article-title":"Examination of multiple trypanosoma cruzi targets in a new drug discovery approach for chagas disease","volume":"58","author":"Beltran-Hortelano","year":"2022","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2026.118678_bb0200","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26154629","article-title":"An overview on target-based drug design against kinetoplastid protozoan infections: human African trypanosomiasis, Chagas disease and leishmaniases","volume":"26","author":"Kourbeli","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.bmc.2026.118678_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112020","article-title":"Advances in the treatment of chagas disease: promising new drugs, plants and targets","volume":"142","author":"Garc\u00eda-Huertas","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.bmc.2026.118678_bb0210","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41579-022-00777-y","article-title":"Anti-trypanosomatid drug discovery: progress and challenges","volume":"21","author":"de Rycker","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.bmc.2026.118678_bb0215","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1039\/C4OB01380H","article-title":"Recent advances in development of imidazo[1,2-a]pyrazines: synthesis, reactivity and their biological applications","volume":"13","author":"Goel","year":"2015","journal-title":"Org Biomol Chem"},{"key":"10.1016\/j.bmc.2026.118678_bb0220","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.2217\/fmb-2023-0044","article-title":"Antifungal efficacy of imidazo[1,2-a]pyrazine based thiosemicarbazones and thiazolidinediones against Sporothrix species","volume":"18","author":"Gon\u00e7alves de Lima Neto","year":"2023","journal-title":"Future Microbiol"},{"key":"10.1016\/j.bmc.2026.118678_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112956","article-title":"In vitro identification of imidazo[1,2-a]pyrazine-based antileishmanial agents and evaluation of l. major casein kinase 1 inhibition","volume":"210","author":"Bazin","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118678_bb0230","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ejmech.2015.09.002","article-title":"Synthesis, antileishmanial activity and cytotoxicity of 2,3-diaryl- and 2,3,8-trisubstituted imidazo[1,2-a]pyrazines","volume":"103","author":"Marchand","year":"2015","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118678_bb0235","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ejmech.2012.10.048","article-title":"Synthesis and biological evaluation of 2,3-diarylimidazo[1,2-a]pyridines as antileishmanial agents","volume":"58","author":"Marhadour","year":"2012","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118678_bb0240","first-page":"3323","article-title":"Pharmacophore-guided optimization of the hit compound CTN1122 in the design of promising imidazo[1,2-a]pyrazine derivatives targeting the casein kinase 1 for antileishmanial therapy","volume":"8","author":"Tisseur","year":"2025","journal-title":"RSC Med Chem"},{"key":"10.1016\/j.bmc.2026.118678_bb0245","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202400862","article-title":"Investigating the c2 modulation of the imidazo[1,2-a]pyrazine-based hit compound CTN1122: synthesis, in vitro antileishmanial activity, cytotoxicity and casein kinase 1 inhibition","volume":"20","author":"Tisseur","year":"2025","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmc.2026.118678_bb0250","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1039\/c0md00085j","article-title":"Development of second generation amidinohydrazones, thio- and semicarbazones as trypanosoma cruzi inhibitors bearing benzofuroxan and benzimidazole 1,3-dioxide core scaffolds","volume":"1","author":"Merlino","year":"2010","journal-title":"Med Chem Commun"},{"key":"10.1016\/j.bmc.2026.118678_bb0255","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1021\/acs.jcim.2c01566","article-title":"Experimental and computational study of aryl-thiosemicarbazones inhibiting cruzain reveals reversible inhibition and a stepwise mechanism","volume":"63","author":"Martins","year":"2023","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.bmc.2026.118678_bb0260","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.chemosphere.2018.01.175","article-title":"Galleria mellonella larvae allow the discrimination of toxic and non-toxic chemicals","volume":"198","author":"Allegra","year":"2018","journal-title":"Chemosphere"},{"key":"10.1016\/j.bmc.2026.118678_bb0265","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1021\/jm4016284","article-title":"Design, synthesis, and structure-activity relationship studies of novel fused heterocycles-linked triazoles with good activity and water solubility","volume":"57","author":"Cao","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118678_bb0270","unstructured":"Saxty G, Murray CW, Berdini V, et al. Imidazo-condensed bicycles as inhibitors of discoidin domain receptors (DDRS)- WO2015004481A1. (n.d.). Deposit: 11 July 2013. Publication: 15 January 2015."},{"key":"10.1016\/j.bmc.2026.118678_bb0275","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1016\/S0040-4039(01)91034-2","article-title":"A general procedure for mild and rapid reduction of aliphatic and aromatic nitro compounds using ammonium formate as a catalytic hydrogen transfer agent","volume":"25","author":"Ram","year":"1984","journal-title":"Tetrahedron Lett"},{"key":"10.1016\/j.bmc.2026.118678_bb0280","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1016\/j.bmcl.2014.03.079","article-title":"Scaffold hopping approach to a new series of smoothened antagonists","volume":"24","author":"Lu","year":"2014","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2026.118678_bb0285","unstructured":"Gold software, version 5.2, Cambridge Crystallographic Data Centre. Cambridge, UK, Accessed November 2017. http:\/\/www.ccdc.cam.ac.uk\/solutions\/csd-discovery\/components\/gold\/."},{"key":"10.1016\/j.bmc.2026.118678_bb0290","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.bmcl.2004.10.023","article-title":"Discovery of potent thiosemicarbazone inhibitors of rhodesain and cruzain","volume":"15","author":"Fujii","year":"2005","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2026.118678_bb0295","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1021\/jm030549j","article-title":"Synthesis and structure\u2013activity relationships of parasiticidal thiosemicarbazone cysteine protease inhibitors against plasmodium falciparum, trypanosoma brucei, and trypanosoma cruzi","volume":"47","author":"Greenbaum","year":"2004","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118678_bb0300","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1016\/S0960-894X(03)00756-X","article-title":"Synthesis and evaluation of isatins and thiosemicarbazone derivatives against cruzain, falcipain-2 and rhodesain","volume":"13","author":"Chiyanzu","year":"2003","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2026.118678_bb0305","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1021\/jm010459j","article-title":"Synthesis and structure-activity relationship study of potent trypanocidal thiosemicarbazone inhibitors of the trypanosomal cysteine protease cruzain","volume":"45","author":"Du","year":"2002","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118678_bb0310","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1021\/jm901070c","article-title":"Quantitative analyses of aggregation, autofluorescence, and reactivity artifacts in a screen for inhibitors of a thiol protease","volume":"53","author":"Jadhav","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118678_bb0315","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1128\/AAC.04601-14","article-title":"Synthesis of a sugar-based thiosemicarbazone series and structure-activity relationship versus the parasite cysteine proteases rhodesain, cruzain, and schistosoma mansoni cathepsin B1","volume":"59","author":"Fonseca","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2026.118678_bb0320","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1039\/B616314A","article-title":"Stability and equilibria of promiscuous aggregates in high protein milieus","volume":"3","author":"Coan","year":"2007","journal-title":"Mol BioSyst"},{"key":"10.1016\/j.bmc.2026.118678_bb0325","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1007\/s10593-013-1301-6","article-title":"Synthesis of imidazo[1,2-a]pyrazine and imidazo[1,2-a]pyrimidine derivatives","volume":"49","author":"Borisov","year":"2013","journal-title":"Chem Heterocycl Compd"},{"key":"10.1016\/j.bmc.2026.118678_bb0330","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1039\/D0QO00003E","article-title":"Palladium-catalyzed C3-selective C\u2013H oxidative carbonylation of imidazo[1,2-a]pyridines with CO and alcohols: a way to access esters","volume":"7","author":"Wang","year":"2020","journal-title":"Org Chem Front"},{"key":"10.1016\/j.bmc.2026.118678_bb0335","unstructured":"Burdi D, Hubbard R, Schmidt D, Hodgetts KJ. Imidazo-pyrimidine derivatives and their use in the treatment of neurologic disorders. WO 2025\/175247 A1; 2025."},{"key":"10.1016\/j.bmc.2026.118678_bb0340","unstructured":"Chaturvedula, P. V. Novel bicyclic compounds. WO 2022\/087371 A1, 2022."},{"key":"10.1016\/j.bmc.2026.118678_bb0345","unstructured":"Davis O, Heald R, Stockley M, et al. Heterocyclic compounds for use in the treatment of cancer. WO 2023\/067353 A1; 2023."},{"key":"10.1016\/j.bmc.2026.118678_bb0350","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1128\/AAC.40.11.2592","article-title":"Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing beta-galactosidase","volume":"40","author":"Buckner","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2026.118678_bb0355","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1590\/S0074-02762010000200022","article-title":"In vitro and in vivo experimental models for drug screening and development for Chagas disease","volume":"105","author":"Romanha","year":"2010","journal-title":"Mem Inst Oswaldo Cruz"},{"issue":"5","key":"10.1016\/j.bmc.2026.118678_bb0360","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/j.1460-2075.1985.tb03772.x","article-title":"Cultivation in a semi-defined medium of animal infective forms of T. brucei, T. equiperdum, T. evansi, T. rhodesiense and T. gambiense","volume":"4","author":"Baltz","year":"1985","journal-title":"EMBO J"},{"key":"10.1016\/j.bmc.2026.118678_bb0365","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0001-706X(97)00079-X","article-title":"The AlamarBlue\u00ae blue assay to determine drug sensitive of African trypanosome (T. brucei rhodesiense and T. brucei gambiense) in vitro","volume":"68","author":"R\u00e4z","year":"1997","journal-title":"Acta Trop"},{"key":"10.1016\/j.bmc.2026.118678_bb0370","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1016\/j.bmc.2017.02.009","article-title":"Synthesis and biological evaluation of potential inhibitors of the cysteine proteases cruzain and rhodesain designed by molecular simplification","volume":"25","author":"Braga","year":"2017","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2026.118678_bb0375","unstructured":"Spartan\u201808 Tutorial and User's Guide; Wavefunction: Irvine, CA, 2008: http:\/\/www.wavefun.com\/products\/spartan.html [accessed November 2017]."},{"key":"10.1016\/j.bmc.2026.118678_bb0380","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/jcc.20425","volume":"27","author":"Rocha","year":"2006","journal-title":"Comput Chem"},{"key":"10.1016\/j.bmc.2026.118678_bb0385","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jmgm.2011.01.004","article-title":"BINANA: a novel algorithm for ligand-receptor interactions","volume":"29","author":"Durrant","year":"2011","journal-title":"J Mol Graph Modell"},{"key":"10.1016\/j.bmc.2026.118678_bb0390","unstructured":"DeLano, W.L. The PyMOL Molecular Graphics System, DeLano Scientific, San Carlos, CA, 2002: http:\/\/www.pymol.org [accessed November 2017]."}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626001343?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626001343?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T13:04:31Z","timestamp":1783170271000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089626001343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":78,"alternative-id":["S0968089626001343"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118678","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"5,6,7,8-Tetrahydroimidazo[1,2-a]pyrazine-based thiosemicarbazones as anti-Trypanosoma cruzi agents","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118678","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118678"}}